Celebrating Three Years of Progress: Capricor Therapeutics Presents Results from HOPE-2 Study at WMS 2024

San Diego, Oct. 04, 2024 (GLOBE NEWSWIRE) —

Capricor Therapeutics, a leading biotechnology company focusing on innovative cell and exosome-based therapies for rare diseases, has announced the presentation of the three-year safety and efficacy data from its HOPE-2 open-label extension study at the 29th Annual Congress of the World Muscle Society (WMS 2024).

The study will showcase the long-term benefits of Capricor’s lead asset, deramiocel, in the treatment of Duchenne muscular dystrophy (DMD). This breakthrough research will be shared through a late-breaking poster presentation at the conference, scheduled for October 8-12, 2024, in Prague, Czechia.

Implications for Individuals and the World

Effect on Individual Patients:

For individuals living with Duchenne muscular dystrophy, Capricor’s HOPE-2 study results offer hope and promise for improved quality of life. The long-term benefits demonstrated by deramiocel highlight the potential for transformative treatments that may enhance muscle function and overall well-being for DMD patients.

Effect on the World:

The presentation of Capricor’s research findings at WMS 2024 represents a significant advancement in the field of rare disease therapeutics. The innovative approach of using cell and exosome-based therapies showcases the potential for groundbreaking treatments that could benefit not only DMD patients but also individuals with other rare diseases.

Conclusion

As Capricor Therapeutics continues to pioneer advancements in the treatment of rare diseases, the three-year safety and efficacy results from the HOPE-2 study provide a glimpse into the future of healthcare. By focusing on innovative therapies like deramiocel, Capricor is paving the way for improved outcomes and enhanced quality of life for individuals worldwide.